[STW 5/Iberogast: multi-target-action for treatment of functional dyspepsia and irritable bowel syndrome].
Functional gastro-intestinal diseases such as functional dyspepsia and irritable bowel syndrome are a therapeutic challenge, as they are not only characterized by a multitude of symptoms, some of them with severe consequences for affected patients, but are also caused by a multitude of factors. The clinical efficacy of the therapeutics STW 5/Iberogast in these diseases has been proven in a number of randomized prospective clinical studies. Several preclinical studies suggest that its efficacy could be due to its complex composition of nine standardized herbal extracts, which act differently on multiple sites. This principle, which is quite popular in clinical medicine, was introduced as a multi-target therapy for functional bowel disorders. Components of STW 5/Iberogast reduce gastro-intestinal hypersensitivity and act spasmolytic on spastic, tonicising on atonic gastro-intestinal muscle. In addition a stimulating effect on reduced mucus-secretion, an inhibitory effect on enhanced gastric acid secretion and an anti-inflammatory effect have been shown. These effects could explain the clinical efficacy of STW5/Iberogast in a large range of symptoms.
Allescher
Hans-Dieter
HD
Zentrum für Innere Medizin, Gastroenterologie, Hepatologie und Metabolismus, Klinikum Garmisch-Partenkirchen, Akademisches Lehrkrankenhaus der Ludwig-Maximilians-Universität München, Garmisch-Partenkirchen, Germany. hans.allescher@klinikum-gap.de
Wagner
Hildebert
H
D000818:Animals; D004195:Disease Models, Animal; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy*; D006168:Guinea Pigs; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D015201:Meta-Analysis as Topic; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D051381:Rats
D010936:Plant Extracts; C039964:iberogast
Curr Treat Options Gastroenterol. 2004 Aug;7(4):265-272
15238201
Arzneimittelforschung. 2001;51(7):545-53
11505785
Phytomedicine. 2006;13 Suppl 5:122-9
16772111
Phytomedicine. 2006;13 Suppl 5:12-9
16857355
Aliment Pharmacol Ther. 2004 Dec;20(11-12):1279-87
15606389
Digestion. 2004;70(4):257-64
15687728
Z Gastroenterol. 2001 Jul;39(7):511-7
11505331
Scand J Gastroenterol. 2002 May;37(5):617-8; author reply 618-20
12059067
Neurogastroenterol Motil. 2004 Dec;16(6):759-64
15601426
Forsch Komplementarmed Klass Naturheilkd. 2002 Dec;9 Suppl 1:1-20
12618546
Phytomedicine. 2006;13 Suppl 5:51-5
16973340
Phytomedicine. 2006;13 Suppl 5:90-9
16765572
Neurogastroenterol Motil. 2004 Dec;16(6):765-73
15601427
Phytomedicine. 2006;13 Suppl 5:67-74
16978852
Phytomedicine. 2006;13 Suppl 5:45-50
16713223
Phytomedicine. 2006;13 Suppl 5:56-66
16963243
Am J Gastroenterol. 2007 Jun;102(6):1276-83
17378904
Wien Med Wochenschr. 2004 Nov;154(21-22):528-34
15638072
Phytomedicine. 2006;13 Suppl 5:2-11
16859904
Adv Ther. 2003 Jan-Feb;20(1):43-9
12772817
Phytomedicine. 2006;13 Suppl 5:36-44
16777393
Aliment Pharmacol Ther. 2004 Feb 1;19(3):271-9
14984373
Z Gastroenterol. 2002 Jun;40(6):401-8
12055663
Phytomedicine. 2006;13 Suppl 5:75-9
16709451
Phytomedicine. 2006;13 Suppl 5:114-21
16978851